$96.99
0.96%
Nasdaq, Oct 02, 04:00 pm EDT. Closed.
ISIN
US45720L1070
Symbol
INBX

Inhibrx Inc Stock price

$96.99
-27.98 22.39% 1M
+33.46 52.67% 6M
+17.99 22.77% YTD
+61.93 176.60% 1Y
+81.56 528.56% 3Y
+69.47 252.43% 5Y
+78.76 431.98% 10Y
+78.76 431.98% 20Y
Nasdaq, Closing price Fri, Oct 02 2026
-0.94 0.96%
ISIN
US45720L1070
Symbol
INBX
Industry

Is Inhibrx Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.

Key metrics

Basic
Market capitalization
$1.4b
Enterprise Value
$1.5b
Net debt
$42.9m
Cash
$133.3m
Shares outstanding
14.7m
Valuation
P/E
negative
P/S | estimate
- | -
EV/Sales | estimate
- | -
EV/FCF | ex SBC
negative | negative
P/B
negative
Financial Health
Equity Ratio
5.5%
Return on Equity
-1,752.2%
ROCE
-101.3%
ROIC
-
Debt/Equity
-3.3
Share-Based Compensation & Dilution
SBC | % of Revenue
$11.7m | -
SBC as % of FCF
-
SBC Growth 1Y
4.6%
Share Count Growth 1Y
1.6%
Shareholder Yield
-1.6%
Financials
Revenue | estimate
$0.0 | $0.0
EBITDA
$-125.0m
EBIT
$-127.8m
Net Income
$-138.2m
Free Cash Flow | ex SBC
$-131.9m | $-143.6m
Growth
Revenue | estimate
-100.0% | -100.0%
EBITDA
23.9%
EBIT
23.5%
Net Income
15.6%
Free Cash Flow
5.9%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
$-8.8
FCF per Share
$-9.0
Short interest
30.8%
Employees
110
Rev per Employee
$10.0k

Inhibrx Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Inhibrx Inc forecast:

8x Buy
80%
2x Hold
20%

Analyst Opinions

10 Analysts have issued a Inhibrx Inc forecast:

Buy
80%
Hold
20%

Financial data from Inhibrx Inc

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 25 25
32% 32%
-
- Research and Development Expense 100 100
22% 22%
-
-125 -125
24% 24%
-
- Depreciation and Amortization 2.83 2.83
1% 1%
-
EBIT (Operating Income) EBIT -128 -128
23% 23%
-
Net Profit -138 -138
16% 16%
-

In millions USD.

Don't miss a Thing! We will send you all news about Inhibrx Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Inhibrx Inc Stock News

Positive
Reuters
●
27 days ago
Inhibrx Biosciences said on Tuesday its experimental combination cancer drug helped reduce tumors in a ​mid-stage study in patients with a type of ‌head and neck cancer.
Neutral
PRNewsWire
●
27 days ago
First OX40 agonist to demonstrate clinical benefit in a randomized study INBRX-106 plus pembrolizumab delivers a 48.3% cORR and   72.4% of patients remain progression free at 6 months, compared with 26.5% and   42.8%   for pembrolizumab alone Results are most pronounced in HPV+ patients, with   cORR (80.0% vs 33.3%), CR rate (30.0% vs 0%), and PFS6 improvement (90.0% vs 33.0%) vs pembrolizumab ...
Neutral
PRNewsWire
●
about 2 months ago
SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the second quarter of 2026. The biopharmaceutical company has two programs in ongoing clinical trials.
More Inhibrx Inc News

Company Profile

Inhibrx, Inc. engages in researching and developing biotechnology. It is a clinical stage company, which focuses on developing pipeline of novel biologic therapeutic candidates. The firm’s pipeline is focused on oncology, orphan diseases and infectious diseases. It utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The company was founded by Mark Paul Lappe, Quinn Deveraux and Brendan P. Eckelman in April 2010 and is headquartered La Jolla, CA.

Head office United States
CEO Mr. Lappe
Employees 110
Founded 2010
Website inhibrx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today